Avidity Biosciences’ antibody oligonucleotide conjugate has shown signs of efficacy in an early-stage test in patients with a rare muscle-wasting disease.
Just last month, Leerink …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
I’m excited to share our latest free feature: The Psychedelic News Feed. This webpage aims to serve as a one-stop destination for the latest media
Patients and members of the public will be able to more easily take part in impactful research thanks to a new tool developed by the
Ocrevus as an intravenous (IV) infusion administration was approved by the FDA and the EU for primary progressive and relapsing-remitting MS in 2017 and 2018,